Keros Therapeutics, Inc. (KROS)
Automate Your Wheel Strategy on KROS
With Tiblio's Option Bot, you can configure your own wheel strategy including KROS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KROS
- Rev/Share 5.2938
- Book/Share 17.9705
- PB 0.7802
- Debt/Equity 0.0253
- CurrentRatio 19.2872
- ROIC -0.004
- MktCap 569427908.0
- FreeCF/Share 1.0679
- PFCF 13.1471
- PE 135.0053
- Debt/Assets 0.0235
- DivYield 0
- ROE 0.0075
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | KROS | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Jan. 21, 2025 |
| Downgrade | KROS | Wedbush | Outperform | Neutral | -- | $15 | Jan. 17, 2025 |
| Reiterated | KROS | Oppenheimer | -- | Outperform | $102 | $63 | Dec. 16, 2024 |
| Downgrade | KROS | Guggenheim | Buy | Neutral | -- | -- | Dec. 16, 2024 |
| Reiterated | KROS | H.C. Wainwright | -- | Buy | $100 | $47 | Dec. 13, 2024 |
| Downgrade | KROS | William Blair | Outperform | Market Perform | -- | -- | Dec. 12, 2024 |
| Downgrade | KROS | TD Cowen | Buy | Hold | -- | -- | Dec. 12, 2024 |
| Downgrade | KROS | BTIG Research | Buy | Neutral | -- | -- | Dec. 12, 2024 |
| Initiation | KROS | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Initiation | KROS | Guggenheim | -- | Buy | -- | $96 | Sept. 23, 2024 |
News
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process
Read More
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas , May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025. In …
Read More
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
AUSTIN, Texas , May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company's upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025. The presentation can be viewed here.
Read More
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S.
Read More
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas , May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released a public letter to fellow Keros stockholders outlining its concerns with the Company's capital allocation decisions, strategic direction, and prolonged underperformance. In the letter, ADAR1 details the Company's alarming clinical results for two of its three drug candidates — KER-012 and KER-065 — and expresses serious …
Read More
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a year ago.
Read More
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Read More
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:
Read More
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Keros Therapeutics, Inc. (KROS)
- IPO Date 2020-04-08
- Website https://www.kerostx.com
- Industry Biotechnology
- CEO Dr. Jasbir S. Seehra Ph.D.
- Employees 163